全文获取类型
收费全文 | 82616篇 |
免费 | 3480篇 |
国内免费 | 1286篇 |
专业分类
耳鼻咽喉 | 737篇 |
儿科学 | 3388篇 |
妇产科学 | 2035篇 |
基础医学 | 10221篇 |
口腔科学 | 790篇 |
临床医学 | 6184篇 |
内科学 | 13380篇 |
皮肤病学 | 1534篇 |
神经病学 | 5288篇 |
特种医学 | 5360篇 |
外国民族医学 | 5篇 |
外科学 | 12054篇 |
综合类 | 3931篇 |
现状与发展 | 2篇 |
一般理论 | 14篇 |
预防医学 | 10059篇 |
眼科学 | 1403篇 |
药学 | 4908篇 |
5篇 | |
中国医学 | 1556篇 |
肿瘤学 | 4528篇 |
出版年
2024年 | 49篇 |
2023年 | 339篇 |
2022年 | 507篇 |
2021年 | 829篇 |
2020年 | 665篇 |
2019年 | 594篇 |
2018年 | 4270篇 |
2017年 | 4724篇 |
2016年 | 3070篇 |
2015年 | 2120篇 |
2014年 | 2027篇 |
2013年 | 1942篇 |
2012年 | 5890篇 |
2011年 | 4608篇 |
2010年 | 1909篇 |
2009年 | 1512篇 |
2008年 | 2097篇 |
2007年 | 2072篇 |
2006年 | 2134篇 |
2005年 | 11418篇 |
2004年 | 15773篇 |
2003年 | 10467篇 |
2002年 | 2373篇 |
2001年 | 1308篇 |
2000年 | 812篇 |
1999年 | 729篇 |
1998年 | 514篇 |
1997年 | 361篇 |
1996年 | 294篇 |
1995年 | 223篇 |
1994年 | 211篇 |
1993年 | 189篇 |
1992年 | 190篇 |
1991年 | 156篇 |
1990年 | 139篇 |
1989年 | 110篇 |
1988年 | 89篇 |
1987年 | 107篇 |
1986年 | 78篇 |
1985年 | 62篇 |
1984年 | 48篇 |
1983年 | 34篇 |
1982年 | 26篇 |
1981年 | 25篇 |
1980年 | 19篇 |
1979年 | 24篇 |
1978年 | 24篇 |
1977年 | 17篇 |
1974年 | 15篇 |
1970年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Forum for Collaborative HIV Research 《HIV clinical trials》2013,14(1):58-88
AbstractWhile the use of highly active antiretroviral therapy (HAART) has lowered the level of virus in the bloodstream, immune reconstitution may offer additional benefits in maintaining viral suppression and enhancing immune function. New approaches in immune-based therapy (IBT) must be designed to capture endpoints that will allow approval of these agents by regulatory agencies.The challenge is to identify, develop, and validate biomarkers that can serve as endpoints in evaluating the efficacy of immunologic agents in HIV disease.On December 7-8, 2000, the Forum for Collaborative HIV Research sponsored a workshop, “Immune-Based Therapies and HIV Disease.” Some of the questions discussed at that meeting included: ? What are the appropriate indices to measure immune competence? ? What are the appropriate research designs and endpoints for trials evaluating IBTs? ? What can we learn from the research on IBTs in diseases other than HIV? ? What are the requirements of regulatory agencies for the approval of IBTs? This report, prepared as background information for participants attending the December workshop, addresses issues related to these discussion questions. The report provides a review of study designs and endpoints used in clinical trials of selected immunologic agents. Eight ofthese agents have been approved by the U.S. Food and Drug Administration (FDA) for use in disease conditions other than HIV and five agents are under study for use in HIV-infected individuals but are not FDA-approved for use in HIV disease.This report was written by Karen Eddleman, who has derstanding of the medical management of HIV disease and develops recommendations to fill those gaps. The Forum is a public/private partnership, which receives financial support from its governmental and industry members and with in-kind support from its membership within the academic research, patient care, and advocacy communities. For more information about the Forum or to download this report or prior ones, visit the Website at www.hivforum.org. Reprinted with permission from Forum for Collaborative HIV Research (www.hivforum.org).done a remarkable job in identifying and reviewing many difficult references and producing a very reader-friendly report. Alan Landay has provided valuable input andassistance in the creation of this report. Houtan Movafagh provided much needed assistance in finding and copying the many references for this report. June Bray, PhD – Deputy Director 相似文献
992.
993.
994.
Hernando V Sobrino-Vegas P Burriel MC Berenguer J Navarro G Santos I Reparaz J Martínez MA Antela A Gutiérrez F Del Amo J;for CoRIS cohort 《AIDS (London, England)》2012,26(14):1829-1834
OBJECTIVES:: To compare causes of death (CoDs) from two independent sources: National Basic Death File (NBDF) and deaths reported to the Spanish HIV Research cohort [Cohort de adultos con infección por VIH de la Red de Investigación en SIDA CoRIS)] and compare the two coding algorithms: International Classification of Diseases, 10th revision (ICD-10) and revised version of Coding Causes of Death in HIV (revised CoDe). METHODS:: Between 2004 and 2008, CoDs were obtained from the cohort records (free text, multiple causes) and also from NBDF (ICD-10). CoDs from CoRIS were coded according to ICD-10 and revised CoDe by a panel. Deaths were compared by 13 disease groups: HIV/AIDS, liver diseases, malignancies, infections, cardiovascular, blood disorders, pulmonary, central nervous system, drug use, external, suicide, other causes and ill defined. RESULTS:: There were 160 deaths. Concordance for the 13 groups was observed in 111 (69%) cases for the two sources and in 115 (72%) cases for the two coding algorithms. According to revised CoDe, the commonest CoDs were HIV/AIDS (53%), non-AIDS malignancies (11%) and liver related (9%), these percentages were similar, 57, 10 and 8%, respectively, for NBDF (coded as ICD-10). When using ICD-10 to code deaths in CoRIS, wherein HIV infection was known in everyone, the proportion of non-AIDS malignancies was 13%, liver-related accounted for 3%, while HIV/AIDS reached 70% due to liver-related, infections and ill-defined causes being coded as HIV/AIDS. CONCLUSION:: There is substantial variation in CoDs in HIV-infected persons according to sources and algorithms. ICD-10 in patients known to be HIV-positive overestimates HIV/AIDS-related deaths at the expense of underestimating liver-related diseases, infections and ill defined causes. CoDe seems as the best option for cohort studies. 相似文献
995.
Martin E. Stryjewski Peter D. Potgieter Yu-Ping Li Steven L. Barriere Allan Churukian Jeff Kingsley G. Ralph Corey for the TD- Investigators Group 《Antimicrobial agents and chemotherapy》2012,56(11):5476-5483
TD-1792 is a first-in-class glycopeptide-cephalosporin heterodimer that exhibits bactericidal activity against Gram-positive pathogens. We conducted a randomized, double-blind, active-control, phase II trial in patients with complicated skin and skin structure infections caused by suspected or confirmed Gram-positive organisms. Patients 18 to 65 years old were randomized to receive 7 to 14 days of either TD-1792 (2 mg/kg of body weight intravenously [i.v.] every 24 h [q24h]) or vancomycin (1 g i.v. q12h, with dosage regimens adjusted per site-specific procedures). A total of 197 patients were randomized and received at least one dose of study medication. Rates of clinical success at the test-of-cure evaluation were similar in all analysis populations. Among 170 clinically evaluable patients, cure rates were 91.7% and 90.7% in the TD-1792 and vancomycin groups, respectively (95% confidence interval [CI] of −7.9 to 9.7 for the difference). In microbiologically evaluable patients with methicillin-resistant Staphylococcus aureus at baseline (n = 75), cure rates were 94.7% in the TD-1792 group and 91.9% in the vancomycin group. Microbiological eradication of Gram-positive pathogens (n = 126) was achieved in 93.7% and 92.1% of patients in the TD-1792 and vancomycin groups, respectively. Seven patients were discontinued from study medication due to an adverse event (AE): 2 and 5 in the TD-1792 and vancomycin groups, respectively. AEs were of similar types and severities between the two groups, other than pruritus, which was more common in patients who received vancomycin. No patients in the TD-1792 group experienced a serious AE. This study supports further clinical development of TD-1792 in patients with Gram-positive infection. 相似文献
996.
DA Morrow JC Fang DJ Fintel CB Granger JN Katz FG Kushner JT Kuvin J Lopez-Sendon D McAreavey B Nallamothu RL Page JE Parrillo PN Peterson C Winkelman;on behalf of the American Heart Association Council on Cardiopulmonary Critical Care Perioperative Resuscitation Council on Clinical Cardiology Council on Cardiovascular Nursing Council on Quality of Care Outcomes Research 《Circulation》2012,126(11):1408-1428
997.
998.
Latania K. Logan John P. Renschler Sumanth Gandra Robert A. Weinstein Ramanan Laxminarayan for the Centers for Disease Control Prevention Epicenters Program 《Emerging infectious diseases》2015,21(11):2014-2021
The prevalence of carbapenem-resistant Enterobacteriaceae (CRE) infections is increasing in the United States. However, few studies have addressed their epidemiology in children. To phenotypically identify CRE isolates cultured from patients 1–17 years of age, we used antimicrobial susceptibilities of Enterobacteriaceae reported to 300 laboratories participating in The Surveillance Network–USA database during January 1999–July 2012. Of 316,253 isolates analyzed, 266 (0.08%) were identified as CRE. CRE infection rate increases were highest for Enterobacter species, blood culture isolates, and isolates from intensive care units, increasing from 0.0% in 1999–2000 to 5.2%, 4.5%, and 3.2%, respectively, in 2011–2012. CRE occurrence in children is increasing but remains low and is less common than that for extended-spectrum β-lactamase–producing Enterobacteriaceae. The molecular characterization of CRE isolates from children and clinical epidemiology of infection are essential for development of effective prevention strategies. 相似文献
999.
İpek Ulu Yasemin Çekmez Şule Yıldırım Köpük Nida Özer Eser Evrim Yoğurtçuoğlu Pınar Anğın 《The journal of maternal-fetal & neonatal medicine》2019,32(15):2543-2546
Purpose: The aim of the study was to investigate whether maternal serum TSP-1 level was associated with PE.Materials and methods: In our case control study, 84 pregnant women in the third trimester were included. Forty-one of them were healthy and 43 of them were with the diagnosis of PE. The diagnosis was based on the definitions of the National High Blood Pressure Education Program working Group on High Blood Pressure in Pregnancy. Preeclamptic patients were divided into two subgroups as mild and severe. Blood pressure (BP) of pregnant women were obtained in left-side lying position using a mercury sphygmomanometer after at least 10 minutes of rest. Ten milliliters of venous blood was taken from every pregnant women and dispensed into lithium heparin and serum was obtained. Samples were stored at ?80?°C until analyzed. Serum TSP-1 level was measured using enzyme-linked immunosorbent assay (ELISA). All tests were two-tailed and p < .05 was considered to be statistically significant.Results: TSP-1 level was significantly lower in PE group than in controls (p?=?.003). Platelet counts were similar in two groups (p = .26). TSP-1 levels were significantly lower in severe PE than in mild PE cases. According to the subgroup analysis, TSP-1 level was found significantly lower in severe preeclampsia group compared to control group (p = .015).Conclusions: In light of the association between endothelial dysfunction and preeclampsia, we claim that lower levels of TSP-1 which is released mostly from endothelial cells seem to reflect disease severity in PE. Our study reveals that maternal serum TSP-1 levels decrease in pregnant women presenting with PE and TSP-1 may be a new biomarker for the detection of PE and even severity of it. Further studies especially prospective ones with greater numbers of cases are needed. 相似文献
1000.